Form 4: GE HealthCare CEO Jan Makela Reports Stock Transactions
SEC Form 4 Filing
Jan Makela, CEO of Imaging at GE HealthCare Technologies Inc., reports the withholding of shares for tax obligations and the award of restricted stock units and an employee stock option.
Summary
- On March 1, 2024, Jan Makela, CEO of Imaging at GE HealthCare Technologies Inc., reported several transactions involving GE HealthCare common stock.
- Shares were withheld to satisfy tax obligations related to the vesting of restricted stock units and performance stock units.
- Makela was also awarded restricted stock units representing the right to receive 8,088 shares of GE HealthCare common stock, vesting in three tranches between September 1, 2025, and September 1, 2027.
- Additionally, Makela received an employee stock option for 23,006 shares, also vesting in three tranches between September 1, 2025, and September 1, 2027.
- Following these transactions, Makela directly owns 63,348 shares of GE HealthCare common stock and holds options for 23,006 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The transactions reflect standard executive compensation practices and alignment with company performance. There are no red flags or concerning details.
Positives
- The award of restricted stock units and employee stock options aligns Makela's interests with the long-term performance of GE HealthCare.
- The vesting schedule of the awards encourages continued service and commitment from Makela.
Future Outlook
The restricted stock units and stock options vest over a three-year period, indicating a long-term incentive structure.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common compensation practices for executives in publicly traded companies, including those in the healthcare technology sector.
- Companies like Siemens Healthineers and Philips also utilize similar equity-based compensation plans to incentivize their leadership teams.
- The vesting schedules and grant sizes are generally aligned with industry benchmarks for executive compensation.
Stakeholder Impact
- The transactions have a minor impact on shareholders, providing transparency into executive compensation.
- Employees may be indirectly affected by the incentive structure for the CEO, which is designed to drive company performance.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transactions: withholding of shares for tax obligations, award of restricted stock units and employee stock option. |
| 03/01/2024 | Date employee stock options become exercisable. |
| 09/01/2025 | First vesting date (33%) for restricted stock units and employee stock options. |
| 09/01/2026 | Second vesting date (33%) for restricted stock units and employee stock options. |
| 09/01/2027 | Final vesting date (34%) for restricted stock units and employee stock options. |
| 03/05/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.